This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: The Institute of Cancer Research: Royal Cancer Hospital. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: The Innovative Contributions of Jonathan Neil Dunn
Introduction
Jonathan Neil Dunn is a notable inventor based in Saffron Walden, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target proliferative disorders such as cancer. His work is characterized by a commitment to advancing medical science through innovative solutions.
Latest Patents
Jonathan Neil Dunn holds a patent for compounds of Formula I, which are designed to inhibit RAS-effector protein-protein interactions. This invention is particularly relevant for the treatment of various diseases, including cancer. The patent highlights the potential of these compounds in pharmaceutical compositions, showcasing their importance in modern medicine. He has 1 patent to his name.
Career Highlights
Throughout his career, Dunn has worked with prestigious institutions such as The Institute of Cancer Research: Royal Cancer Hospital and Oxford University Innovation Ltd. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field of cancer treatment.
Collaborations
Dunn has collaborated with esteemed colleagues, including Terrence Rabbitts and Camilo Quevedo. These partnerships have further enriched his research and have played a crucial role in the advancement of his innovative projects.
Conclusion
Jonathan Neil Dunn's work exemplifies the spirit of innovation in the pharmaceutical industry. His contributions to cancer treatment through his patented compounds demonstrate the impact of dedicated research and collaboration in addressing critical health challenges.